PDHX

Across TCGA pan-cancer cohorts, PDHX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PDHX data layer compared with 19 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PDHX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PDHX expression acts as an unfavorable survival marker, although some lineages such as OV and PDAC show a favorable association.

CCRCC, OV, and PDAC are the cancer types where PDHX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.600	1.000	.003	23	view →
OV	DFS	Median	All	0.923	0.650	.029	16	view →
PDAC	OS	Median	IV	0.836	0.491	.024	7	view →
GBM	DFS	Median	All	0.243	0.484	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PDHX–CCRCC (DFS)

Open the CCRCC breakdown →